Phentermine vs Semaglutide 2026: Full Comparison

Phentermine vs Semaglutide: The Fundamentals

These are the two most widely used prescription weight loss medications in the US — and two very different pharmacological approaches. Tmates' compounded GLP-1's phentermine ($149/mo) is a CNS stimulant approved for short-term use that works through norepinephrine release to suppress appetite and increase energy. Tmates GLP-1 program's compounded semaglutide ($249/mo) is a GLP-1 receptor agonist approved for long-term weight management that works through hormone receptor activation to normalize appetite biology, eliminate food noise, and slow gastric emptying.

The clinical performance gap is significant. STEP-1 documented 14.9% average body weight reduction at 68 weeks for semaglutide. Phentermine's documented average is 3–7% over 12-week courses — reflecting both the lower potency of CNS stimulation versus GLP-1 agonism AND the limitation on treatment duration (phentermine is approved short-term only, while semaglutide can be continued indefinitely). For a 250-pound patient: semaglutide averages approximately 37 pounds lost; phentermine averages 7.5–17.5 pounds in 12 weeks.

When phentermine makes sense over semaglutide: cost is a real barrier ($149 vs $249/mo — $1,200/year difference); injection aversion is present and oral semaglutide doesn't appeal; a short-term kickstart to weight loss momentum is the goal rather than a long-term program. When semaglutide is clearly superior: you want clinically significant, sustained weight reduction; you have metabolic risk factors (prediabetes, cardiovascular risk) where semaglutide's SELECT trial data matters; you're prepared to commit to 6+ months of treatment; or the food noise elimination is the specific benefit you're seeking. See the detailed semaglutide vs phentermine comparison page. Also compare: tirzepatide vs phentermine and semaglutide vs tirzepatide. Explore the full weight loss category.